Awards to the Institution

Award Value
Tools and Technologies III: Larry Couture Development of a scalable, practical, and transferable GMP-compliant suspension culture-based differentiation process for cardiomyocyte production from human embryonic stem cells. $899,728
Early Translational III: Stephen Forman Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells $5,217,004
Disease Team Research I: John Zaia ZIinc Finger Nuclease-Based Stem Cell Therapy for AIDS $14,536,969
Basic Biology IV: Yanhong Shi Modeling Alexander disease using patient-specific induced pluripotent stem cells $1,367,172
SEED Grant: Timothy O'Connor Sources of Genetic Instability in Human Embryonic Stem Cells. $327,311
Creativity Awards: Paul Salvaterra Creativity Award Program in Stem Cell Biology for California High School Students $260,825
Tools and Technologies I: Larry Couture Development of Suspension Adaptation, Scale-up cGMP Banking and Cell Characterization Technologies for hESC Lines $882,929
Disease Team Planning: Michael Barish Genetically-modified neural stem cells for treatment of high-grade glioma $55,000
New Faculty I: Tiziano Barberi Skeletal muscle development from hESC and its in vivo applications in animal models of muscular dystrophy $131,840
Early Translational II: Yanhong Shi Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell $1,835,983
Strategic Partnership III Track A: John Zaia A Phase I, Open-Label Study to Assess the Safety, Feasibility and Engraftment of Zinc Finger Nucleases (ZFN) CCR5 Modified Autologous CD34+ Hematopoietic Stem/Progenitor Cells with Escalating Doses of Busulfan in HIV-1 (R5) Infected Subjects with Suboptim $5,583,438
Basic Biology III: Jiing-Kuan Yee Use of human iPS cells to study spinal muscular atrophy $1,268,868
Early Translational II: David DiGiusto Development of RNA-based approaches to stem cell gene therapy for HIV $3,097,160
Alpha Stem Cell Clinics: John Zaia The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. $8,000,000
Research Training II: Michael Barish Research Training Program in Stem Cell Biology $2,500,143
Disease Team Research I: Karen Aboody Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials $17,890,623
Icon for xls export